Easing Manufacturing Bottlenecks to Meet the Potential of mRNA

The use of mRNA technologies gained widespread recognition with its successful implementation in COVID-19 vaccines. However, manufacturing mRNA faces multiple challenges because of the novelty of its production and scaling processes and the lack of regulatory guidance, production capacity, and wide-spread manufacturing know-how.

Access insights from a panel of experts who convened to discuss strategies for overcoming these issues and creating a landscape where production of more potent mRNA vaccines is both more scalable and more accessible.

Don’t miss your free report from Scrip, presented in partnership with TriLink BioTechnologies.

Whitepaper

Complete the form below to download the content.

* - marks a required field

Email Address

First Name

Last Name

Address

City

Country

Province

State

Post Code

Phone

Answer the following questions about your organization below:

Company Name

How many people are employed by your organization?

What is your company's revenue?

In which industry do you work?

Job Function

Job Title

Job Level

Department

By clicking ‘Submit’ you agree to our Terms of Use. We take your privacy seriously. For more information please read our Privacy Policy.